Management of colorectal cancer during the COVID-19 pandemic: Recommendations from a statewide multidisciplinary cancer collaborative
Brian C. Brajcich MD, MS
Surgical Outcomes and Quality Improvement Center (SOQIC), Department of Surgery, Northwestern Medicine, Chicago, Illinois, USA
Search for more papers by this authorAl B. Benson MD
Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
Search for more papers by this authorGerald Gantt Jr. MD
Department of Surgery, University of Illinois College of Medicine, Chicago, Illinois, USA
Search for more papers by this authorOliver S. Eng MD
Department of Surgery, University of Chicago, Chicago, Illinois, USA
Search for more papers by this authorRobert W. Marsh MD
Department of Medical Oncology, NorthShore University HealthSystem, University of Chicago, Chicago, Illinois, USA
Search for more papers by this authorMary F. Mulcahy MD
Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
Search for more papers by this authorBlase N. Polite MD, MPP
Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
Search for more papers by this authorBenjamin D. Shogan MD
Department of Surgery, University of Chicago, Chicago, Illinois, USA
Search for more papers by this authorAnthony D. Yang MD, MS
Surgical Outcomes and Quality Improvement Center (SOQIC), Department of Surgery, Northwestern Medicine, Chicago, Illinois, USA
Search for more papers by this authorCorresponding Author
Ryan P. Merkow MD, MS
Surgical Outcomes and Quality Improvement Center (SOQIC), Department of Surgery, Northwestern Medicine, Chicago, Illinois, USA
Correspondence Ryan P. Merkow, MD, MS, Surgical Outcomes and Quality Improvement Center, Department of Surgery, Northwestern Medicine, 633 N Saint Clair St., 20th Floor, Chicago, IL 60611, USA.
Email: [email protected]
Search for more papers by this authorBrian C. Brajcich MD, MS
Surgical Outcomes and Quality Improvement Center (SOQIC), Department of Surgery, Northwestern Medicine, Chicago, Illinois, USA
Search for more papers by this authorAl B. Benson MD
Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
Search for more papers by this authorGerald Gantt Jr. MD
Department of Surgery, University of Illinois College of Medicine, Chicago, Illinois, USA
Search for more papers by this authorOliver S. Eng MD
Department of Surgery, University of Chicago, Chicago, Illinois, USA
Search for more papers by this authorRobert W. Marsh MD
Department of Medical Oncology, NorthShore University HealthSystem, University of Chicago, Chicago, Illinois, USA
Search for more papers by this authorMary F. Mulcahy MD
Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
Search for more papers by this authorBlase N. Polite MD, MPP
Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
Search for more papers by this authorBenjamin D. Shogan MD
Department of Surgery, University of Chicago, Chicago, Illinois, USA
Search for more papers by this authorAnthony D. Yang MD, MS
Surgical Outcomes and Quality Improvement Center (SOQIC), Department of Surgery, Northwestern Medicine, Chicago, Illinois, USA
Search for more papers by this authorCorresponding Author
Ryan P. Merkow MD, MS
Surgical Outcomes and Quality Improvement Center (SOQIC), Department of Surgery, Northwestern Medicine, Chicago, Illinois, USA
Correspondence Ryan P. Merkow, MD, MS, Surgical Outcomes and Quality Improvement Center, Department of Surgery, Northwestern Medicine, 633 N Saint Clair St., 20th Floor, Chicago, IL 60611, USA.
Email: [email protected]
Search for more papers by this authorAbstract
COVID-19 has resulted in significant disruptions in cancer care. The Illinois Cancer Collaborative (ILCC), a statewide multidisciplinary cancer collaborative, has developed expert recommendations for triage and management of colorectal cancer when disruptions occur in usual care. Such recommendations would be applicable to future outbreaks of COVID-19 or other large-scale disruptions in cancer care.
CONFLICT OF INTERESTS
The authors declare that there are no conflict of interests.
REFERENCES
- 1Czeisler MÉ, Marynak K, Clarke KEN, et al. Delay or avoidance of medical care because of COVID-19-related concerns—United States, June 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(36): 1250-1257.
- 2Baum A, Kaboli PJ, Schwartz MD. Reduced in-person and increased telehealth outpatient visits during the COVID-19 pandemic. Ann Intern Med. 2020; 174: 129-131.
- 3Disis ML. Oncology and COVID-19. JAMA. 2020; 324(12): 1141-1142.
- 4 Illinois Cancer Collaborative. 2020. http://ilcancer.org/. Accessed November 30, 2020.
- 5Wanis KN, Patel SVB, Brackstone M. Do moderate surgical treatment delays influence survival in colon cancer? Dis Colon Rectum. 2017; 60(12): 1241-1249.
- 6Hangaard Hansen C, Gogenur M, Tvilling Madsen M, Gogenur I. The effect of time from diagnosis to surgery on oncological outcomes in patients undergoing surgery for colon cancer: a systematic review. Eur J Surg Oncol. 2018; 44(10): 1479-1485.
- 7Grass F, Behm KT, Duchalais E, et al. Impact of delay to surgery on survival in stage I-III colon cancer. Eur J Surg Oncol. 2020; 46(3): 455-461.
- 8Iversen LH, Antonsen S, Laurberg S, Lautrup MD. Therapeutic delay reduces survival of rectal cancer but not of colonic cancer. Br J Surg. 2009; 96(10): 1183-1189.
- 9Ramos M, Esteva M, Cabeza E, Campillo C, Llobera J, Aguilo A. Relationship of diagnostic and therapeutic delay with survival in colorectal cancer: a review. Eur J Cancer. 2007; 43(17): 2467-2478.
- 10Petrelli F, Sgroi G, Sarti E, Barni S. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann Surg. 2016; 263(3): 458-464.
- 11Smith JJ, Strombom P, Chow OS, et al. Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol. 2019; 5(4):e185896.
- 12 Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 2012; 13(11): 1152-1160.
- 13Seymour MT, Morton D. FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. J Clin Oncol. 2019; 37(15_suppl): 3504.
- 14 Network NCC. Rectal Cancer (version 6.2020). https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Accessed November 30, 2020.
- 15Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol. 2004; 72(1): 15-24.
- 16Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012; 30(31): 3827-3833.
- 17Erlandsson J, Holm T, Pettersson D, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017; 18(3): 336-346.
- 18Grothey A, Sobrero AF, Shields AF, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018; 378(13): 1177-1188.
- 19Sobrero A, Lonardi S, Rosati G, et al. FOLFOX or CAPOX in stage II to III colon cancer: efficacy results of the italian three or six colon adjuvant trial. J Clin Oncol. 2018; 36(15): 1478-1485.
